藥明康德(603259.SH)：子公司擬認繳1500萬美元的投資基金份額
格隆匯9月27日丨藥明康德(603259.SH)公佈，2021年9月27日，公司全資子企業WuXi PharmaTech Healthcare Fund I L.P.(以下簡稱“WuXiFundI”)與Longwood Fund VI GP, LLC(“普通合夥人”)及Longwood Management, LLC(“管理公司”)簽署Amended and Restated Limited Partnership Agreement(“合夥協議”)，以及簽署Investor Questionnaire(“投資人問卷”)，約定由WuXi Fund I認繳Longwood Fund VI, L.P.(“投資基金”)的1500萬美元的投資基金份額(以下簡稱“本次投資”)，約佔已募集投資基金份額的19.16%(WuXi Fund I所持投資基金份額比例將隨投資基金後續從第三方投資機構及個人募資而進一步稀釋)。
截至公吿日，WuXi Fund I尚未支付投資款，後續WuXi Fund I將以自有資金根據合夥協議的要求履行投資款的支付義務。投資基金預計募集總額不超過2.04億美元。WuXi Fund I本次認繳1500萬美元后，投資基金已募集7829.35萬美元資金。
本次投資基金與Longwood Fund V,L.P.同由Christoph Westphal博士團隊進行管理。本次投資基金將主要投資北美洲和英國的藥物、治療方法及相關領域的創新生物技術企業。
本次投資有助於公司在獲取投資收益的同時，通過美國本土的知名醫療健康風險投資機構的行業網絡，瞭解北美洲和英國的產業前沿動態，深度挖掘該區域優質生物科技和醫療健康企業的潛在投資機會，協助業務部門與潛在客户建立密切合作關係，進一步深化和拓展公司一體化醫藥研發平台能力。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app！
Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.
